HLB Pep Co., Ltd.

HLB Pep Co., Ltd. is a bio-venture company that manufactures and sells peptide biomaterials and drug raw materials in South Korea and internationally. It offers GMP, generic, custom, and catalog peptides, along with other services. The company is developing AGM-130, which is in Phase I for triple negative breast cancer. Its preclinical products include AGM-331 for anti-cancer therapy, AGM-380 for viral infection, AGM-290 for infections caused by multidrug-resistant bacteria, AGM-212 for Type 2 Diabetes, AGM-217 for Type 2 diabetes and obesity, and AGM-260 for Ulcerative colitis. Formerly known as Anygen Co., Ltd., it changed its name to HLB Pep Co., Ltd. in April 2025. Founded in 2000, it is headquartered in Gwangju-si, South Korea.